US FDA Communication Ahead Of Major Actions Could Counter Misinformation, Ex-Official Says

 
• By Kate Rawson
  
Josh Sharfstein speaks during Prevision Policy's 2021 BioPharma Congress
Josh Sharfstein argues that FDA should be more proactive in combating misinformation. • Source: Biopharma Congress screenshot
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA

More from Agency Leadership